Australia's most trusted
source of pharma news
Posted 15 October 2024 AM
ASX-listed LTR Pharma has announced remarkable results from the completed pivotal clinical study for its erectile dysfunction nasal spray Spontan, showing a 470 per cent faster absorption rate compared to oral treatments, and positioning the product as a potential global market disruptor.
The results have bolstered LTR's commercialisation prospects with the company in ongoing global partnering and licensing discussions. Additionally, the data will support LTR's engagement with key regulatory bodies, including the FDA and TGA.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.